Demyelination News and Research

RSS

A demyelinating disease is any disease of the nervous system in which the myelin sheath of neurons is damaged. This impairs the conduction of signals in the affected nerves, causing impairment in sensation, movement, cognition, or other functions depending on which nerves are involved.

Researchers one step closer to unmasking the cause of familial MS

A new study has uncovered mutations in 12 genes that may be responsible for the familial type of multiple sclerosis (MS).

7 Jun 2019

Innovative compound offers a new therapeutic approach to treat multiple sclerosis

Multiple sclerosis is an autoimmune disease that affects more than 2.3 million people worldwide. This debilitating condition periodically shutters communication between the brain and other parts of the body, resulting in symptoms that range from numbness and tingling in the arms and legs to blindness and paralysis.

22 Feb 2019

Study reveals mechanism behind failed remyelination in MS

Researchers have discovered that in adult stem cells, the activation of a specific transcription factor induces pathological quiescence and that this is deactivated in MS.

18 Dec 2018

Study provides new way to treat multiple sclerosis

Nerve cells stripped of their insulation can no longer carry vital information, leading to the numbness, weakness and vision problems often associated with multiple sclerosis. A new study shows an overlooked source may be able to replace that lost insulation and provide a new way to treat diseases like MS.

27 Nov 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Environmental conditions may drive development of multiple sclerosis

A new Tel Aviv University study finds that certain environmental conditions may precipitate structural changes that take place in myelin sheaths in the onset of multiple sclerosis. Myelin sheaths are the "insulating tape" surrounding axons; axons carry electrical impulses in neurons.

16 Oct 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

Researchers discover new subtype of multiple sclerosis

Cleveland Clinic researchers have discovered a new subtype of multiple sclerosis, providing a better understanding of the individualized nature of the disease.

22 Aug 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Leukemia itself may increase risk for long-term neurocognitive problems in survivors

Leukemia itself, not just side effects related to its treatment, may increase the risk for long-term problems with attention, organization and related neurocognitive skills in survivors of the most common childhood cancer, according to research from St. Jude Children's Research Hospital. The study appears today in the journal JAMA Oncology.

29 Mar 2018

Popular allergy drug may reduce relapses in patients with neuromyelitis optica

The addition of cetirizine (the popular allergy medication sold under the brand name Zyrtec) to standard therapy is safe, well-tolerated, and may reduce relapses in patients with neuromyelitis optica (NMO), a rare and severe disease that causes inflammation and demyelination (damage to the myelin - the protective coating of nerve cells), primarily in the optic nerve (optic neuritis), spinal cord (myelitis), and brainstem.

2 Feb 2018

Researchers use novel PET tracer to assess myelin damage in mouse models of MS

The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the hallmark of the immune-mediated neurological disorder multiple sclerosis.

12 Jan 2018

Myelin sheaths restore impaired nervous system over the long haul

In the central nervous system of humans and all other mammals, a vital insulating sheath composed of lipids and proteins around nerve fibers helps speed the electrical signals or nerve impulses that direct our bodies to walk, talk, breathe, swallow or perform any routine physical act.

24 Oct 2017

Gene therapy effectively stabilizes progression of cerebral adrenoleukodystrophy, trial reveals

In a recent clinical trial, a gene therapy to treat cerebral adrenoleukodystrophy (CALD) -- a neurodegenerative disease that typically claims young boys' lives within 10 years of diagnosis -- effectively stabilized the disease's progression in 88 percent of patients, researchers from the Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Massachusetts General Hospital report today.

4 Oct 2017

Study identifies promising drug candidate for treating demyelinating diseases

Brain functions are maintained by the neural network. Neural network is formed by the connection between the neurite, and this connection is supported by the wrapping of myelin.

26 Aug 2017

Common acne medication can slow progress of relapsing-remitting MS, trial shows

A Canadian clinical trial led by researchers at the University of Calgary's Hotchkiss Brain Institute, at the Cumming School of Medicine, shows that minocycline, a common acne medication, can slow the progress of relapsing-remitting multiple sclerosis (MS) in people who have recently experienced their first symptoms.

1 Jun 2017

Demyelination may not be good indicator of MS progression, study finds

A study by researchers from Queen Mary University of London establishes for the first time the extent of neuronal loss in the brain of a person with MS over their life and finds that demyelination may not be as good an indicator of disease progression as previously thought.

10 May 2017

Nose2Brain project aims to develop better therapy for multiple sclerosis

Medically active substances are normally distributed via the blood - either directly by injection into the bloodstream or indirectly, for example through the digestive tract after oral administration.

27 Apr 2017

Genentech grant funds home-based telemedicine program for treating MS patients

Multiple sclerosis (MS) clinicians face continued challenges in optimizing neurological care, especially for people with advanced MS living in medically underserved communities. Because of insurmountable geographical and physical challenges, patients cannot always travel to neurology office appointments.

10 Mar 2017